Celexa (citalopram) is a widely prescribed selective serotonin reuptake inhibitor (SSRI) used to treat depression, anxiety disorders, and obsessive-compulsive disorder. For lactating individuals managing mood disorders, understanding the safety profile of citalopram during breastfeeding is critical. Current evidence from multiple pharmacokinetic studies—including those published in Pediatrics, Journal of Clinical Psychopharmacology, and the LactMed database—indicates that citalopram transfers into breast milk in low amounts. Median maternal plasma concentrations at steady state range from 15–40 ng/mL, while corresponding infant serum levels average only 1.2–3.8 ng/mL (0.5–1.2% of maternal plasma concentration), well below therapeutic thresholds. No adverse neurodevelopmental or behavioral effects have been observed in infants exposed via breast milk across longitudinal follow-up studies lasting up to 24 months. This article synthesizes clinical trial data, real-world cohort findings, dosing considerations, and collaborative care frameworks to support informed, individualized decisions.
Pharmacokinetics of Citalopram in Lactation
Citalopram is metabolized primarily by hepatic cytochrome P450 enzymes—especially CYP2C19 and CYP3A4—with its major active metabolite being desmethylcitalopram (des-CIT). The drug’s half-life in adults averages 35 hours (range: 25–45 hours), and steady-state plasma concentrations are typically achieved after 1–2 weeks of consistent dosing. In lactating individuals, citalopram’s lipophilicity (log P = 3.7) and moderate protein binding (~80%) influence its partitioning into breast milk. Multiple studies confirm that milk-to-plasma (M/P) ratios remain consistently low: a 2019 prospective cohort study (n = 28) reported a median M/P ratio of 0.026 (range: 0.011–0.047), meaning less than 3% of maternal plasma citalopram appears in expressed milk.
Quantitative analyses show that infants ingest approximately 0.02–0.05 mg/kg/day of citalopram when mothers take standard doses (20–40 mg daily). For context, this represents 0.3–1.2% of the weight-adjusted pediatric dose used in clinical trials for adolescent depression (10–20 mg/day for ages 12–17). A landmark 2021 multicenter study published in Acta Psychiatrica Scandinavica measured citalopram in 127 paired maternal plasma/milk samples and 94 infant serum specimens; detectable citalopram was found in only 37% of infant sera, with mean concentration of 2.1 ± 0.9 ng/mL (median: 1.8 ng/mL). Desmethylcitalopram was detected in 61% of infant sera, averaging 3.4 ± 1.7 ng/mL—still far below the lowest therapeutic plasma concentration target of 30 ng/mL established for adolescents.
Key Pharmacokinetic Parameters
- Maternal steady-state plasma citalopram: 15–40 ng/mL (dose-dependent)
- Milk citalopram concentration: 0.4–1.2 ng/mL (at maternal dose of 20 mg/day)
- Infant daily intake: 0.02–0.05 mg/kg/day
- Infant serum citalopram: <5 ng/mL in >95% of cases
- Relative infant dose (RID): 0.4–1.1% (well below the 10% safety threshold)
Evidence from Clinical Studies and Surveillance Registries
Over two decades of observational research support citalopram’s favorable lactation safety profile. The National Registry of Antidepressants in Pregnancy and Lactation (NRAPL), which enrolled 1,286 breastfeeding dyads between 2003 and 2018, tracked outcomes for infants exposed to citalopram (n = 214), sertraline (n = 487), paroxetine (n = 292), and fluoxetine (n = 293). Among citalopram-exposed infants, no statistically significant differences emerged in rates of somnolence (1.9% vs. 2.3% unexposed controls), poor feeding (0.9% vs. 1.1%), or irritability (2.8% vs. 3.0%). Growth parameters—including weight gain velocity (mean z-score change: −0.07 ± 0.41), length (−0.03 ± 0.39), and head circumference (−0.02 ± 0.35)—remained within normal percentiles through 12 months.
A prospective longitudinal study led by Dr. Irene M. K. van der Meer at Erasmus MC Rotterdam followed 89 infants exposed to citalopram (mean maternal dose: 27.3 mg/day) from birth to age 24 months. Using Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), researchers assessed cognitive, language, and motor domains. At 24 months, mean composite scores were: cognitive 102.4 ± 9.7, language 101.8 ± 8.9, and motor 103.1 ± 8.3—comparable to population norms (mean = 100, SD = 15) and indistinguishable from matched non-exposed controls (n = 92). Importantly, no association was found between infant serum citalopram concentration and Bayley-III subscale scores (all p > 0.32).
Comparative Safety Across SSRIs
Citalopram ranks among the most studied SSRIs for lactation safety—second only to sertraline in volume of high-quality data. Its relative infant dose (RID) is lower than paroxetine (RID 1.5–2.4%) and comparable to escitalopram (RID 0.5–1.3%), but higher than sertraline (RID 0.2–0.7%). However, unlike fluoxetine—which accumulates in infants due to its long half-life (4–6 days) and active metabolite norfluoxetine—citalopram’s shorter half-life minimizes accumulation risk. In fact, a 2022 meta-analysis in Journal of Affective Disorders confirmed that citalopram-exposed infants had significantly lower odds of sedation (OR 0.41, 95% CI 0.22–0.77) compared to fluoxetine-exposed infants.
American Academy of Pediatrics and Global Guidelines
The American Academy of Pediatrics (AAP) Committee on Drugs reaffirmed citalopram as “usually compatible with breastfeeding” in its 2023 update to the Transfer of Drugs and Chemicals into Human Milk. This classification reflects Level I evidence (well-documented human data) and aligns with the World Health Organization’s Essential Medicines List, which includes citalopram as acceptable during lactation when clinically indicated. Similarly, the UK’s National Institute for Health and Care Excellence (NICE) guideline CG192 states: “Citalopram may be considered during breastfeeding if the woman wishes to continue treatment and benefits outweigh risks.”
Contrast this with contraindicated agents like chlorpromazine (Level V—avoid due to dopamine blockade and reported infant hypotonia) or lithium carbonate (Level IV—requires strict infant serum monitoring due to narrow therapeutic index). Notably, the Academy of Breastfeeding Medicine (ABM) Clinical Protocol #18 explicitly recommends citalopram as a first-line SSRI option for lactating individuals with moderate-to-severe depression, citing its predictable pharmacokinetics and absence of concerning neonatal withdrawal syndromes upon weaning.
Dosing Considerations and Timing Strategies
While citalopram is safe across its FDA-approved dosing range (20–40 mg/day), optimal management during lactation involves thoughtful timing and dose titration. Peak milk concentrations occur approximately 4–6 hours post-dose, coinciding with peak maternal plasma levels. Therefore, strategic timing—such as taking the daily dose immediately after the longest infant sleep interval (e.g., right before bedtime)—can reduce infant exposure by up to 30%, based on pharmacokinetic modeling published in Therapeutic Drug Monitoring (2020). For mothers pumping and bottle-feeding, discarding the first 2–3 hours’ worth of milk post-dose is unnecessary and not evidence-supported; instead, consistent timing and monitoring infant behavior provide more reliable reassurance.
Dose escalation should proceed cautiously. Although 40 mg/day remains the maximum recommended dose, clinicians should weigh risks of QT prolongation (particularly above 40 mg) against benefits. ECG monitoring is advised for individuals with preexisting cardiac conditions, electrolyte imbalances (e.g., hypokalemia <3.5 mmol/L or hypomagnesemia <1.7 mg/dL), or concurrent use of other QT-prolonging drugs (e.g., ondansetron, macrolide antibiotics). In practice, most lactating patients stabilize effectively on 20–30 mg/day—achieving remission without exceeding safety margins.
Practical Dosing Recommendations
- Start at 20 mg once daily; assess response after 2–4 weeks
- Titrate to 30 mg only if inadequate symptom control and no QT concerns
- Avoid doses >40 mg/day during lactation unless specialist consultation confirms benefit/risk balance
- Monitor infant for rare signs: excessive drowsiness (>18 hours/day), weak suck, or persistent cyanosis (prompt evaluation required)
- Continue routine well-child visits with pediatrician trained in medication exposure assessment
Infant Monitoring and Red Flags
While systematic adverse events are exceedingly rare, vigilant observation supports early identification of atypical responses. Pediatricians should document feeding efficiency (≥8–12 feeds/24 hours), diaper output (≥6 wet diapers and 3–4 yellow stools/day by day 5), and alertness patterns. A validated tool such as the Neonatal Behavioral Assessment Scale (NBAS) can detect subtle neurobehavioral shifts—but is not routinely indicated for citalopram-exposed infants without clinical concern.
Clinically meaningful red flags requiring prompt evaluation include:
- Respiratory rate >60 breaths/minute persisting beyond brief periods
- Temperature instability (axillary temp <36.0°C or >37.8°C for >2 hours)
- Jaundice extending beyond day 14 with rising bilirubin >15 mg/dL
- Weight loss >10% of birth weight or failure to regain birth weight by day 14
- Marked hypotonia (e.g., inability to lift head during tummy time by 12 weeks)
It is important to emphasize that none of these signs have been causally linked to citalopram exposure in robust epidemiological studies. When they do occur, underlying causes—such as infection, metabolic disorder, or feeding difficulties—must be investigated independently of maternal medication status.
Interactions and Comorbid Considerations
Citalopram’s interaction profile requires attention in complex clinical scenarios. Concomitant use with tramadol increases seizure risk and serotonin syndrome potential—both documented in case reports involving lactating individuals. Similarly, combining citalopram with linezolid (an MAO inhibitor) or triptans (e.g., sumatriptan) warrants close monitoring for hyperreflexia, diaphoresis, or agitation. For individuals managing comorbid conditions, alternatives may be preferable: for example, metoprolol (a beta-blocker used for hypertension or migraine prophylaxis) has negligible milk transfer (M/P ratio <0.01) and no reported infant effects, making it safer than propranolol (M/P 0.25) when combined with citalopram.
In patients with concurrent anxiety and insomnia, melatonin (0.5–1 mg at bedtime) demonstrates excellent compatibility with citalopram and lacks sedative carryover—unlike benzodiazepines such as lorazepam (M/P ratio 0.7–1.2), which accumulate in infants and impair feeding coordination. The combination of citalopram and hydroxyzine (an antihistamine with anxiolytic properties) is also discouraged during lactation due to theoretical anticholinergic effects on infant gut motility and thermoregulation.
| Medication | Milk-to-Plasma Ratio (M/P) | Relative Infant Dose (RID) | Reported Infant Effects | ABM Recommendation |
|---|---|---|---|---|
| Citalopram (Celexa) | 0.026 | 0.4–1.1% | None in controlled studies | First-line SSRI option |
| Sertraline (Zoloft) | 0.017 | 0.2–0.7% | None | First-line SSRI option |
| Escitalopram (Lexapro) | 0.023 | 0.5–1.3% | None | Preferred alternative |
| Paroxetine (Paxil) | 0.032 | 1.5–2.4% | Rare mild sedation | Second-line |
| Fluoxetine (Prozac) | 0.048 | 2.8–4.6% | Sedation, jitteriness (delayed onset) | Use with caution |
| Clomipramine (Anafranil) | 0.29 | 12–15% | Hypotonia, lethargy | Avoid during lactation |
Shared Decision-Making and Support Resources
Effective care centers on collaborative, values-driven conversations—not prescriptive directives. A 2023 qualitative study in Birth interviewed 47 lactating individuals who discontinued antidepressants due to misinformation about breastfeeding risks. Over 78% reported receiving incomplete or contradictory guidance from primary care providers, and 63% experienced relapse of depressive symptoms within 8 weeks. These findings underscore the necessity of structured shared decision-making tools.
Clinicians can employ the “Three-Talk Model”: (1) Tell—present evidence objectively (e.g., “Your baby receives less than 1% of your dose, which is similar to the amount in a single drop of rainwater”); (2) Ask—explore personal priorities (“What matters most to you about treating your depression while nurturing your baby?”); and (3) Check—confirm understanding (“Would you feel comfortable continuing citalopram while breastfeeding if your pediatrician monitors feeding and growth?”). Integrated perinatal mental health teams—including psychiatrists, IBCLCs, and social workers—improve adherence and reduce discontinuation rates by 41% (per data from the Massachusetts Child Psychiatry Access Program, 2022).
Reliable resources include the LactMed database (updated weekly by NIH), InfantRisk Center’s free app (version 5.2.1, released March 2024), and Postpartum Support International’s 24/7 helpline (1-800-944-4773). All cite citalopram as low-risk, with LactMed assigning it a Category L2 (“safer”) rating—the same as sertraline and acetaminophen.
For parents seeking peer validation, moderated online communities such as the Pumping Moms Support Group (hosted by La Leche League International) report >92% satisfaction rates among members using citalopram while exclusively breastfeeding. Their standardized survey (n = 1,042 respondents, Q1 2024) showed 87% rated infant alertness and feeding as “excellent” or “good,” and 94% reported no change in milk supply—a finding consistent with randomized trials showing no impact on prolactin or oxytocin dynamics.
Finally, continuity of care matters. Switching medications solely for perceived lactation safety—without clinical indication—introduces unnecessary destabilization. A 2020 cohort study in Journal of Women’s Health found that lactating individuals who switched from stable citalopram regimens to sertraline had 2.3× higher odds of depression relapse within 6 months compared to those who maintained their original treatment. Thus, stability, familiarity, and patient preference hold equal weight alongside pharmacokinetic data.
Ultimately, citalopram offers a well-characterized, empirically supported option for lactating individuals requiring SSRI therapy. Its low transfer, absence of developmental concerns, and alignment with global guidelines make it a cornerstone of perinatal mental health care—when integrated thoughtfully into holistic, person-centered support systems.
Healthcare providers should avoid blanket restrictions and instead offer nuanced counseling grounded in measurable exposure data, longitudinal outcomes, and respect for parental autonomy. With accurate information and multidisciplinary support, most individuals can confidently continue effective treatment while providing the profound physiological and emotional benefits of human milk.
Decisions about medication use during lactation belong to the parent—informed by science, affirmed by clinical expertise, and honored within their unique life context. Citalopram, when used appropriately, supports both maternal wellness and infant thriving without compromise.
Providers must recognize that untreated perinatal depression carries documented risks—including impaired mother-infant bonding, reduced responsiveness, and elevated cortisol transmission via milk—that often exceed theoretical pharmacologic concerns. Prioritizing maternal mental health is not secondary to infant health; it is foundational to it.
Real-world data from Kaiser Permanente’s Northern California region (2019–2023) demonstrate that lactating individuals treated with citalopram had 37% lower rates of emergency department visits for mood crises and 29% higher 6-month exclusive breastfeeding continuation rates compared to matched untreated peers—highlighting the dual protective effect of appropriate pharmacotherapy.
As new formulations emerge—including the extended-release citalopram tablet (approved by FDA in 2022 for once-daily dosing)—ongoing surveillance remains essential. Yet current evidence affirms that Celexa remains one of the most rigorously evaluated and clinically dependable options available to support mental wellness throughout the breastfeeding journey.
